Funding for this research was provided by:
GEFLUC (Groupement des Entreprises Françaises dans la Lutte contre le Cancer) Languedoc-Roussillon
SIRIC Montpellier Cancer (INCa-DGOS-Inserm 6045)
Received: 3 April 2018
Accepted: 7 January 2019
First Online: 30 January 2019
Ethics approval and consent to participate
: This study was reviewed and approved by the Montpellier Cancer Institute Institutional Review Board. Considering the retrospective, non-interventional nature of this study, no specific consent was deemed necessary by the clinical research review board of the Montpellier Cancer Institute.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.